{"id":866786,"date":"2025-07-07T08:09:00","date_gmt":"2025-07-07T12:09:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/"},"modified":"2025-07-07T08:09:00","modified_gmt":"2025-07-07T12:09:00","slug":"lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/","title":{"rendered":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada"},"content":{"rendered":"<h2>\nExclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO and CLERMONT-FERRAND, France, July  07, 2025  (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Th\u00e9a (\u201cTh\u00e9a\u201d) announced an exclusive license and commercialization agreement for Th\u00e9a to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Th\u00e9a is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products.<\/p>\n<p align=\"justify\">Under the terms of the licensing and commercialization agreement, LENZ will be eligible to receive over $70 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on net sales. Th\u00e9a will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in Canada.<\/p>\n<p align=\"justify\">\u201cTh\u00e9a is a leading company in eyecare in key markets around the world and was a natural choice for LENZ when looking for a highly capable commercial partner in Canada. With its strong position in commercializing eye drops, Th\u00e9a is uniquely positioned to bring the benefits of LNZ100 to patients in this key market,\u201d said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. \u201cThis agreement represents our third commercialization partnership outside the United States for LNZ100, as we continue to be focused on maximizing patient access to this important therapy worldwide.\u201d<\/p>\n<p align=\"justify\">Jean-Fr\u00e9d\u00e9ric Chibret, President of Th\u00e9a, commented: \u201cCanada is an important part of Th\u00e9a\u2019s international development, and we have been active in the country for several years. Our local team plays an essential role in supporting both patients and eye care professionals. This partnership with LENZ will expand our portfolio with a promising therapy targeting a prevalent condition that affects millions of adults. We see strong potential for LNZ100 in Canada and look forward to initiating the registration process and making the treatment available to Canadian healthcare providers and their patients.<\/p>\n<p align=\"justify\">In October 2024, LENZ announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application.<\/p>\n<p align=\"justify\">\n        <strong>About LENZ Therapeutics<br \/><\/strong>LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ\u2019s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for \u201call eyes, all day\u201d. LENZ is headquartered in San Diego, California. For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vfyQj-ixPvY_-WOf5OzoraLhTk0QVIoC8QMEbgPcAVb6vOm-OCo2_nuIFDwNpnrL52TAZ0rne7MttHfU_N0Yog==\" rel=\"nofollow\" target=\"_blank\">LENZ-Tx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Th\u00e9a<\/strong><br \/>\n        <br \/>Th\u00e9a is the leading independent European pharmaceutical company specializing in the research, development, and commercialization of ophthalmic products. Headquartered in Clermont-Ferrand, France, this family-owned company employs over 2,000 people and has built a strong international presence through a network of more than 35 independent subsidiaries and offices across Europe, North Africa, the Americas, and the Middle East. All products are manufactured in Europe\u201460% in France\u2014and are available in 75 countries worldwide. In 2024, Th\u00e9a reported revenues of \u20ac970 million. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B_PVPz9-ovJNeiVuABGOcSKGZ8vhjNrg90g-e8SVaMhgi4sbR3uHBo3hdCrmRToqEMHObhVEAfNarzdpqIyYWxhJSShOhOtGadaBtwWXlQnOWn-kiIYkFyCpAlCQfRmL\" rel=\"nofollow\" target=\"_blank\">www.laboratoires-Th\u00e9a.com<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G7JoK4TEigoAzp73x7_OW3PyFlSGNegYvp2n4-LXLK8S_0G1n7JfQIYZ9pxPHol_95tt25JHFV1FpDzIHwKN1Uy69yuVOEzSe0-EsCbFkXZxCmIcKD_PxhH-HSmGn41IrDjadL9A1CswxUpyeUCOhkffun4z4ddu657S0X6gSRQCg-0XwbPhLdm94nb5Sf2J6T6CbVQDBeOPPImbRCfiUg==\" rel=\"nofollow\" target=\"_blank\">Laboratoires Th\u00e9a\u00a0: Pr\u00e9sentation | LinkedIn<\/a><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\n            <strong>Contacts:<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Dan Chevallard<br \/>LENZ Therapeutics<br \/><a href=\"mailto:IR@LENZ-Tx.com\" rel=\"nofollow\" target=\"_blank\">IR@LENZ-Tx.com<\/a><\/td>\n<td>Julie Ahmed<br \/>Laboratoires Th\u00e9a<br \/><a href=\"mailto:julie.ahmed@theapharma.com\" rel=\"nofollow\" target=\"_blank\">julie.ahmed@theapharma.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDhmMjkwYjEtNDA3NS00ODE2LTljZjYtYTJhMDRmMDUzODM4LTEyNzU1MzctMjAyNS0wNy0wNy1lbg==\/tiny\/LENZ-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Th\u00e9a (\u201cTh\u00e9a\u201d) announced an exclusive license and commercialization agreement for Th\u00e9a to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Th\u00e9a is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products. Under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866786","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Th\u00e9a (\u201cTh\u00e9a\u201d) announced an exclusive license and commercialization agreement for Th\u00e9a to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Th\u00e9a is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products. Under &hellip; Continue reading &quot;LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T12:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada\",\"datePublished\":\"2025-07-07T12:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/\"},\"wordCount\":688,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/\",\"name\":\"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\",\"datePublished\":\"2025-07-07T12:09:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/","og_locale":"en_US","og_type":"article","og_title":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk","og_description":"Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Th\u00e9a (\u201cTh\u00e9a\u201d) announced an exclusive license and commercialization agreement for Th\u00e9a to register and commercialize LNZ100 for the treatment of presbyopia in Canada. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, which has a US FDA PDUFA date of August 8, 2025. Th\u00e9a is an independent pharmaceutical company specialized in the research, development and commercialization of eye-care products. Under &hellip; Continue reading \"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T12:09:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada","datePublished":"2025-07-07T12:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/"},"wordCount":688,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/","name":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=","datePublished":"2025-07-07T12:09:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTI2NSM3MDMyMTc3IzIyNjM5ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-and-laboratoires-thea-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LENZ Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866786"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866786\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}